OINDPnews


Aptar Pharma banner

Business

Pulmatrix and Cipla resolve dispute over Pulmazole funding

According to Pulmatrix, a dispute between Pulmatrix and Cipla over funding related to the development of Pulmazole intraconazole DPI (PUR 1900) has been resolved. In May 2021, Pulmatrix announced that Cipla had failed to provide 50% of the development costs for Pulmazole and had therefore breached the terms of their development and commercialization agreement for the … [Read more...] about Pulmatrix and Cipla resolve dispute over Pulmazole funding

Perrigo launches Marinomed’s Carragelose nasal spray in France and Scandinavia

Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray is being marketed for the prevention of respiratory viruses under the name Physiomer in the Scandinavian countries and as Phytosun … [Read more...] about Perrigo launches Marinomed’s Carragelose nasal spray in France and Scandinavia

CF Foundation, Innoviva make equity investments in Armata Pharmaceuticals

Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company's common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata, has invested a further $4 million. The funds will be used to support further development of the company's lead … [Read more...] about CF Foundation, Innoviva make equity investments in Armata Pharmaceuticals

ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said. According to the announcement, funds will also be used for expanding the company's pipeline and for adding manufacturing capabilities. Earlier … [Read more...] about ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray

Shandong Luoxin Pharmaceutical will pay $2 million up front plus milestone payments of up to $20 million to acquire exclusive rights to develop, manufacture, and commercialize Marninomed's Budesolv budesonide nasal spray in China, the company has announced. In April 2019, Marinomed announced that a Phase 3 trial of Budesolv for the treatment of allergic rhinitis had … [Read more...] about Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray

Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis

Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec's mSAS supercritical fluid particle engineering technology. The first project for the two companies under the new agreement will be development of a dry powder formulation of teriparatide … [Read more...] about Biosidus partners with Crystec on development of dry powder teriparatide for the treatment of osteoporosis

Bayer and Meda file patent infringement suit after Apotex submits ANDA for generic of Astepro Allergy nasal spray

Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer's NDA for Astepro Allergy for non-prescription treatment of allergic rhinitis in June 2021. According to the complaint filed by Bayer … [Read more...] about Bayer and Meda file patent infringement suit after Apotex submits ANDA for generic of Astepro Allergy nasal spray

US PTAB finds that the majority of the claims in a Tyvaso patent challenged by Liquidia are unpatentable

According to Liquidia Corporation, an inter partes review by the US Patent Trial and Appeal Board (PTAB) regarding US Patent No. 9,604,901, which is listed in the Orange Book as one of 7 patents covering United Therapeutics' Tyvaso inhalation solution, determined that only 2 out of 9 claims included in the patent were potentially patentable based on a review of prior … [Read more...] about US PTAB finds that the majority of the claims in a Tyvaso patent challenged by Liquidia are unpatentable

Glenmark launches Tavulus tiotropium bromide DPI in Spain

Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights to market the tiotropium dry powder inhaler in Western Europe. The company recently launched the tiotropium DPI in the UK, where it is called … [Read more...] about Glenmark launches Tavulus tiotropium bromide DPI in Spain